ethiodized oil

Trade name: ethiodol

Small moleculeapproved

Approved

Mar 31, 1954

Iodized oil, also known as ethiodized oil, brand name Lipiodol, is a medication derived from poppyseed oil and iodine. When given by injection, it is a radio-opaque contrast agent that is used to outline structures in radiological investigations. When given orally or by intramuscular injection once or twice a year, it prevents endemic goitre in remote communities. It has an additional use in gastric variceal obliteration as a dilutant that does not affect polymerization of cyanoacrylate. — Wikipedia

Clinical trial activity

10 trials · 15 clinical orgs · 1 marketing orgs

Phase 1
3
Phase 2
8
Phase 3
5
Phase 4
0

Earliest trial started Jun 1, 2001 (NCT00027768)

Timeline

1950s

  1. Mar 31, 1954

    Guerbet — Earliest FDA Approval

  2. Mar 31, 1954

    Guerbet — NDA Secondary Org

  3. Mar 31, 1954

    Guerbet — NDA Organization

2000s

  1. Jan 1, 2001

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetOTHER

    Diagnostic agent

  • UnclearUnclear

    Unclear unclear

Approval history

  • approvedPriority reviewMar 31, 1954

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Black box warning

Sources

Also known as

  • eoe 13
  • eoe 13
  • eoe-13
  • ethiodiol
  • ethiodized oil
  • ethiodized oil
  • ethiodized oil
  • ethiodized oil
  • ethiodized oil
  • ethiodized oil emulsion 13
  • ethiodol
  • ethiodol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06497140Phase 3Sep 30, 2024Assistance Publique - Hôpitaux de Paris, Government of France
NCT06130072Phase 3Nov 10, 2023Ain Shams University
NCT05672108Phase 2May 12, 2023City of Hope National Medical Center, National Cancer Institute (NCI)
NCT05490381Phase 1Jan 5, 2023Guerbet, University of Washington
NCT05435014Phase 1/Phase 2 (Phase 2)Sep 13, 2022T-ACE Medical Co., Ltd
NCT04728633Phase 2Sep 27, 2021Thomas Jefferson University
NCT04753918Early Phase 1 (Phase 1)Mar 31, 2021Taoyan County Governmnet, Taiwan, Taoyuan General Hospital
NCT01966133Phase 3Aug 1, 2011Fudan University
NCT00870558Phase 3Jun 1, 2005CHU Edouard Herriot, University of Lyon
NCT00027768Phase 3Jun 1, 2001Government of Singapore
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (15)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Ain Shams UniversityAcademic/Hospital1112023
Assistance Publique - Hôpitaux de ParisAcademic/Hospital1112024
CHU Edouard HerriotAcademic/Hospital1012005
City of Hope National Medical CenterAcademic/Hospital1112023
Fudan UniversityAcademic/Hospital1112011
Government of FranceGovernment1012024
Government of SingaporeGovernment1112001
GuerbetFor profit1012023
National Cancer Institute (NCI)Government1012023
T-ACE Medical Co., LtdFor profit1112022
Taoyan County Governmnet, TaiwanGovernment1012021
Taoyuan General HospitalAcademic/Hospital1112021
Thomas Jefferson UniversityAcademic/Hospital1112021
University of LyonAcademic/Hospital1112005
University of WashingtonAcademic/Hospital1112023
15 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
GuerbetFor profitNDA2Mar 31, 1954
GuerbetFor profitNDAMar 31, 1954